Chiesi Expands Rare Disease Portfolio, Acquires KalVista for $1.9 Billion

Why It Matters

The deal accelerates Chiesi’s entry into the fast‑growing rare‑immunology space and offers patients a more convenient, non‑injectable option for a life‑threatening condition, potentially reshaping market dynamics.

Key Takeaways

• Chiesi to buy KalVista for $1.9 billion cash.
• Adds EKTERLY, first oral on‑demand HAE therapy.
• Expands Chiesi’s rare‑immunology portfolio toward $6.5 billion target.
• Aims to shift rare disease treatment from injectables to oral.
• Deal closes Q3 2026, pending regulatory approval.

Pulse Analysis

The rare‑disease sector is experiencing a surge of investment as biotech firms chase high‑margin, unmet‑need markets. Oral formulations are especially attractive because they simplify administration, improve adherence, and reduce healthcare costs compared with injectable biologics. This trend is evident across immunology, neurology, and metabolic disorders, where patients and payers alike demand more patient‑centric solutions. By acquiring KalVista, Chiesi positions itself at the forefront of this movement, leveraging EKTERLY’s unique on‑demand oral profile to differentiate from traditional HAE injectables such as C1‑esterase inhibitors.

EKTERLY (sebetralstat) received regulatory approval in the United States, Europe, and Japan, and its launch in 2025 generated robust early sales, driven by its rapid onset and ease of use during acute HAE attacks. KalVista’s pipeline and commercial expertise complement Chiesi’s global infrastructure, enabling rapid scale‑up of distribution and market penetration. The $1.9 billion all‑cash price reflects a premium for the drug’s differentiated mechanism and the strategic value of adding a first‑in‑class oral therapy to Chiesi’s rare‑disease portfolio, which already includes respiratory and neonatal products.

Industry analysts view the acquisition as a bellwether for larger pharmaceutical players eyeing rare‑immunology opportunities. The shift toward oral agents could pressure incumbents to innovate or acquire similar assets, intensifying competition in a niche yet lucrative market. For patients, broader access to EKTERLY may translate into fewer emergency department visits and improved quality of life. As regulatory approvals proceed and the deal closes in Q3 2026, the transaction is likely to set a precedent for future high‑value deals targeting oral solutions for rare conditions.